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To the Editor: Increasing numbers of HIV/AIDS-infected individuals 
have presented to medical casualty at Charlotte Maxeke Johannesburg 
Academic Hospital (CMJAH) after attempting suicide by overdosing 
on their antiretroviral therapy. Since 2009, medical gastro-enterology 
at CMJAH has been the primary specialty unit for cases of accidental 
or intentional overdose. Psychiatry and other medical sub-specialties 
are consulted as needed. Our unit sees approximately 1 case a month 
of accidental/intentional overdose with antiretrovirals. Between 
January and September 2010, 6% of all overdoses seen at CMJAH 
were of antiretroviral origin. Supportive care is provided and patients 
undergo psychiatric evaluation. 
The information available on overdoses with antiretrovirals is from 
studies in developed countries, where intravenous drug users and 
men who have sex with men make up the bulk of the HIV-positive 
population. This differs significantly from South Africa, which now 
has the largest antiretroviral programme in the world. With little 
evidence related to this type of overdose, are we approaching the 
management, monitoring and follow-up of these patients correctly? 
Case report
A 42-year-old woman presented to the medical casualty department 
after taking 60 lamivudine (3TC) tablets and 60 stavudine (D4T) tablets 
for the purpose of deliberate self-harm. She had been on highly active 
antiretroviral therapy (HAART) for 2 years. Stressors leading to the suicide 
attempt included the diagnosis of HIV and side-effects of HAART.
Initial complaints included abdominal pain and nausea but no 
vomiting. Clinical examination and biochemical investigations (full 
blood count, urea and electrolytes, salicylate and paracetamol levels, 
liver function tests, lipase level and international normalised ratio) 
yielded no abnormalities. Blood gas measurement performed in 
casualty showed a normal pH and lactate level. Unfortunately drug 
level monitoring for the specific antiretrovirals ingested could not be 
performed, as this resource is not available at CMJAH.
The patient was treated with activated charcoal, approximately 
2 hours after ingesting the HAART overdose; metaclopramide for 
nausea and vomiting and hyoscine butylbromide for abdominal 
cramps were administered intravenously. On admission a diagnosis 
of adjustment disorder with major depressive disorder and suicidality 
was made. Citalopram 40 mg daily was started and after 5 days she was 
discharged for follow-up in the psychiatric outpatient department. 
She was to continue receiving HAART from her local clinic.
This case identified many unanswered questions and prompted 
a review of the relevant literature. Ethics approval was obtained to 
review admission records from the University of the Witwatersrand 
Ethics Committee.
Discussion
The literature search yielded few case reports describing accidental 
or intentional overdose on antiretroviral agents. Three of these 
concerned confusion between nevirapine and nelfinavir, where the 
opposite dosages were taken.1 Two of these patients presented with 
severe fatigue, hypersomnia and nausea, and the third patient, a 
neonate who had accidentally been given an overdose of nevirapine, 
had asymptomatic neutropenia and hyperlactataemia.2 In one case 
of an accidental overdose of ritonavir the patient experienced 
tiredness, headache, dry mouth, circumoral paraesthesiae, dizziness 
and disequilibrium of gait, and an electrocardiogram revealed a 
prolonged QT interval.3 There is only 1 report of pharmacokinetic 
follow-up over 10 days after acute intoxication with nevirapine.4 
In all cases, symptomatic and supportive treatment was the only 
treatment necessary and all patients recovered fully.1-4 In a review of 
79 cases of indinavir overdose the authors concluded that side-effects 
of overdose, whether acute or chronic, were generally consistent 
with the safety profile of the drug.5 Only one series of 4 case 
studies reported life-threatening side-effects and 1 death related 
to zidovudine overdose in neonates, where zidovudine-induced 
neutropenia led to opportunistic bacterial infections.6   
Before the advent of HAART, AIDS-related deaths were the leading 
cause of death in HIV-positive patients. With the introduction 
of successfully implemented HAART in the USA, the number of 
AIDS-related deaths in HIV-infected individuals has decreased 
while the number of deaths due to non-AIDS-related diseases and 
malignancies has increased.7,8 In Alberta, Canada, post-HAART, 32% 
of all deaths in HIV-positive patients are non-AIDS related (7% of 
these being due to suicide).9 Other studies suggest that 10 - 30% of 
these suicides are due to overdose.10 
As HIV is a chronic disease, it is not surprising that the increased 
rate of suicidal ideation and behaviour in HIV-positive individuals 
parallels that seen in other medically ill groups with life-threatening 
disorders.9,11 Individuals with HIV/AIDS have an increased rate of 
suicidal ideation, suicide attempts and completed suicide.9 Their 
risk factors for suicide include current stressors (e.g. unemployment, 
bereavement and stigmatisation), poor adaptive functioning, 
hopelessness, neuroticism and decreased social support.9
All these factors are thought to be due to the combination of 
increased susceptibility to mental illness as a result of HIV diagnosis 
and infection, opportunistic infection, socio-economic factors and 
neuropsychiatric side-effects of antiretrovirals. The latter may also 
be exacerbated when antiretrovirals interact with other drugs taken 
concurrently.12,13
Most previous case reports deal with accidental overdoses, in 
which doses are far lower than taken by people intending to harm 
themselves. Toxic effects of antiretrovirals in the acute setting are 
similar to their chronic side-effects, so patients who have overdosed 
deliberately can be expected to present with the same side-effects that 
would be expected after prolonged use.5,14
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Management in our unit remains supportive with a biopsychosocial 
approach dealing with complications as and when they arise. Many 
unanswered remaining questions deserve further study.
•    Should specific treatment be instituted, e.g. antidotes or the use 
of haemodialysis to aid the excretion of certain drugs, and is the 
use of activated charcoal beneficial?
•    Does length of time on HAART before overdose influence the 
complication rate?
•    Can drug level monitoring help confirm the diagnosis, estimate 
toxicity and estimate when HAART can be restarted after 
overdose, where the half-life of drugs taken in overdose can be 
prolonged compared with therapeutic dosing?10
•    Do we risk causing a ‘functional monotherapy’ when stopping 
combinations of antiretrovirals with different half-lives at the 
same time, and will this lead to acquisition of new drug-related 
mutations?15
•    Is our health care system, specifically mental health care, 
equipped to handle this new challenge?
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